Business Insider

Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of ...

- Six-month data from PaTH Forward open-label extension support potential use of TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism – - Conference call Tuesday, September 29 at ...
Nasdaq

Clinical data demonstrate the potential of TransCon PTH as a hormone replacement therapy for adults with hypoparathyroidism

Over 90 percent of subjects demonstrated independence from standard-of-care (calcium ≤ 500 mg/day and active vitamin D = 0 µg/day) and 76 percent of subjects eliminated all supplements while: No ...
Nasdaq

Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of ...

COPENHAGEN, Denmark, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical ...